News for Regeneron Pharmaceuticals Stock (REGN)

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

GlobeNewsWire • 09/27/24

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

GlobeNewsWire • 09/26/24

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Seeking Alpha • 09/25/24

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?

Benzinga • 09/24/24

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea

Zacks Investment Research • 09/24/24

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

Zacks Investment Research • 09/24/24

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Investors Business Daily • 09/23/24

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion

Zacks Investment Research • 09/23/24

The 3 Top Pharma Stocks to Buy in September 2024

24/7 Wall Street • 09/23/24

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

GlobeNewsWire • 09/20/24

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

GlobeNewsWire • 09/20/24

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

Zacks Investment Research • 09/16/24

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GlobeNewsWire • 09/13/24

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Zacks Investment Research • 09/11/24

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

GlobeNewsWire • 09/11/24

Prediction: These 2 Companies Will Split Their Stocks by 2027

The Motley Fool • 09/11/24

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

GlobeNewsWire • 09/11/24

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

GlobeNewsWire • 09/11/24

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

GlobeNewsWire • 09/11/24

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

GlobeNewsWire • 09/11/24

2 Biotech Stocks To Watch In September 2024

Stockmarketcom • 09/11/24

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

GlobeNewsWire • 09/09/24

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

GlobeNewsWire • 09/09/24

Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)

Seeking Alpha • 09/05/24

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

The Motley Fool • 09/05/24